Mammoth Bio CEO on Bayer Pact to Make Crispr Therapies

The video discusses Mammoth Biosciences' collaboration with Bayer to expand gene therapy using novel CRISPR systems, focusing initially on liver diseases. It highlights the potential of CRISPR proteins for in vivo applications and addresses ethical concerns in gene editing. The pandemic's role in accelerating CRISPR-based diagnostics is explored, along with the importance of transparency in scientific endeavors, drawing lessons from the Elizabeth Holmes case.

What is the primary focus of the collaboration between Mammoth and Bayer?

• Developing new CRISPR systems for agricultural use

• Expanding gene therapy platforms with novel CRISPR proteins

• Improving CRISPR systems for cosmetic applications

• Creating CRISPR-based vaccines

Why is the liver chosen as the starting point for CRISPR applications?

• It is the easiest organ to access

• It is the most affected by genetic diseases

• It has a high potential for successful gene editing

• It is the only organ that can be edited

What ethical stance does Mammoth take regarding gene editing?

• Focusing on cosmetic enhancements

• Prioritizing cures for serious genetic diseases

• Allowing unrestricted use of gene editing

• Developing gene editing for agricultural purposes

How has the pandemic influenced the development of CRISPR technologies?

• It halted all CRISPR research

• It accelerated the development of CRISPR diagnostics

• It led to the abandonment of CRISPR projects

• It shifted focus to agricultural applications

What lesson does Mammoth take from the case of Elizabeth Holmes?

• The importance of secrecy in scientific research

• The need for rapid commercialization

• The value of transparency and openness

• The benefits of avoiding public scrutiny